Salud financiera de hoja de balance de Bio-Rad Laboratories
Salud financiera controles de criterios 5/6
Bio-Rad Laboratories tiene unos fondos propios totales de $8.4B y una deuda total de $1.2B, lo que sitúa su ratio deuda/fondos propios en 14.1%. Sus activos y pasivos totales son $11.9B y $3.5B respectivamente. Bio-Rad Laboratories El EBIT de la empresa es de $391.8M, por lo que su ratio de cobertura de intereses es de -8.2. Su tesorería e inversiones a corto plazo ascienden a $1.8B.
Información clave
13.6%
Ratio deuda-patrimonio
US$1.19b
Deuda
| Ratio de cobertura de intereses | -7.1x |
| Efectivo | US$1.61b |
| Patrimonio | US$8.74b |
| Total pasivo | US$3.56b |
| Activos totales | US$12.30b |
Actualizaciones recientes sobre salud financiera
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18
Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Sep 02Recent updates
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?
Feb 07Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?
Dec 17Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?
Oct 02We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?
Jul 30Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 04Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
May 01Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Apr 04Bio-Rad Labs reports Q4 2022 results
Feb 16Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jan 20Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Dec 08Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M
Oct 27A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Oct 14Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal
Oct 12Bio-Rad Laboratories hits 52-week low; down 40% YTD
Sep 19Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Sep 02Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M
Jul 28When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 25Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jul 04Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet
May 02Bio-Rad Offers Value If You Look
Mar 28Bio-Rad Laboratories: Relentless Growth Supports A Bullish Outlook
Dec 25Is Now The Time To Look At Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Dec 10What Is Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Share Price Doing?
Aug 25Análisis de la situación financiera
Pasivos a corto plazo: BIOLos activos a corto plazo ($3.1B) de la empresa superan a sus pasivos a corto plazo ($558.2M).
Pasivo a largo plazo: BIOLos activos a corto plazo ($3.1B) superan a sus pasivos a largo plazo ($2.9B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: BIO tiene más efectivo que su deuda total.
Reducción de la deuda: BIOha pasado de 8.6% a 14.1% en los últimos 5 años.
Cobertura de la deuda: BIOLa deuda de la empresa está bien cubierta por el flujo de caja operativo (31.4%).
Cobertura de intereses: BIO gana más intereses de los que paga, por lo que la cobertura del pago de intereses no es preocupante.